Journal: Molecular Therapy Oncology

Article Title: Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition

doi: 10.1016/j.omton.2026.201226

Figure Lengend Snippet: Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS treated MPC-11 tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.

Article Snippet: MPC-11 murine plasmacytoma cells (CCL-167, American Type Culture Collection, Manassas, VA) were maintained in DMEM supplemented with 10% fetal bovine serum.

Techniques: Clinical Proteomics, Saline

Journal: bioRxiv

Article Title: Ratiometric Fluorescent Protein Biosensors Reveal Citrate Dynamics and Cellular Heterogeneity

doi: 10.64898/2026.04.16.718871

Figure Lengend Snippet: A-B. Pseudo-colored images of HeLa cells expressing ratioCitron1Low ( A ) and ratioCitron1High ( B ) in cytosol before and after addition of citrate. Scale bar: 100 µm. C-D. Δ R / R and Δ F / F values of ratioCitron1Low ( C ) and ratioCitron1High ( D ) versus time upon the addition of citrate. HeLa cells were incubated with 4 μM digitonin for 10 mins before the experiment and a final concentration of 20 mM citrate was added at t = 0 (ratioCitron1Low n = 16, ratioCitron1High n = 19, mean ± SD). E. Time courses of Δ R / R ₀ of ratioCitron1 variants (ratioCitron1Low ( n = 20), ratioCitron1High ( n = 10), ratioCitron1Low-con ( n = 5), ratioCitron1High-con ( n = 5)) expressed in HeLa cells upon the citrate titration. HeLa cells expressing ratioCitron1 variants were treated with digitonin and citrate titration was carried out. The final concentration of citrate is 100 μM at 0 min, 1 mM at 5 min, 10 mM at 10 min (mean ± SD). F-G. Δ R / R values of ratioCitron1 variants expressed in cytosol ( F ) and in mitochondria (mito-ratioCiton1) ( G ) of HeLa cells upon the addition of the ACLY inhibitor of BMS-303141. H. Δ R / R values of ratioCitron1 variants expressed in mitochondria (mito-ratioCitron1) of HeLa cells upon the addition of MPC inhibitor UK-5099 (final concentration: 25 μM). Δ F/F = ( F on - F off )/ F off , and F with excitation 405 nm or 470 nm and emission 518/45 nm. Δ R / R = ( R on - R off )/ R off , and R = ( F with excitation 470 nm and emission 518/45 nm) / ( F with excitation 405 nm and emission 518/45 nm).

Article Snippet: For imaging the treatment with MPC inhibitor UK-5099 (MedChemExpress) and ACLY inhibitor BMS-303141 (MedChemExpress), Hank’s balanced salt solution (HBSS; Nacalai Tesque, 09735-75) and 10 mM HEPES (Nacalai Tesque, 177557-94) was used as imaging buffer.

Techniques: Expressing, Incubation, Concentration Assay, Titration